Target Audience 

The educational design of this activity addresses the needs of dermatologists involved in the treatment of patients with psoriasis. 

Program Overview 

Moderate to severe psoriasis not only presents with skin manifestations, but also carries increased risk for significant systemic effects like cardiovascular disease.  Treatment regimens can range from topicals to systemic therapies, including numerous targeted biologic agents that have different side effect profiles and efficacy rates.  In this activity, expert faculty discuss a patient with psoriasis and significant cardiovascular risk factors who may benefit from targeted biologic therapy.   

Educational Objectives  

After completing this activity, the participant should be better able to:

  • Comprehensively assess patients with psoriasis for potential clinical manifestations, multisystem effects, and patient-reported outcomes 
  • Discuss the clinical profiles and trial results for current and emerging targeted treatment options for psoriasis 
  • Construct treatment regimens for patients with moderate to severe psoriasis based on disease presentation, comorbidities, therapeutic responses, and shared decision making 


Anthony P. Fernandez, MD, PhD 
Assistant Professor of Clinical Medicine, CCLCM 
Director of Medical Dermatology 
W.D. Steck Chair of Clinical Dermatology
Cleveland Clinic
Cleveland, Ohio

Linda Stein Gold, MD 
Vice President, American Academy of Dermatology
Director, Clinical Research, Department of Dermatology
Henry Ford Health
Detroit, Michigan
Division Head, Dermatology, Henry Ford Health
West Bloomfield, Michigan 

Physician Accreditation Statement 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation 

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Education 

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. 

This educational activity for 0.25 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

Global Contact Information 

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Instructions to Receive Credit 

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a minimum score of 100% on the posttest, and complete the program evaluation. 

Fee Information 

There is no fee for this educational activity. 

Disclosures of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.   

All relevant financial relationships have been mitigated.  

The faculty have the following relevant financial relationships with ineligible companies: 

Anthony P. Fernandez, MD, PhD:   Consultant: AbbVie Inc., Bristol Myers Squibb Company, UCB, Inc.; Contracted research: AbbVie Inc., Alexion Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer Inc.; Honoraria: AbbVie Inc., Bristol Myers Squibb Company, Kyowa Kirin, inc., UCB, Inc.; Speakers Bureau: AbbVie Inc., Kyowa Kirin, Inc., Mallinckrodt Pharmaceuticals, Novartis Pharmaceuticals Corporation 

Linda Stein Gold, MD:   Consultant/Contracted Research/Honoraria: AbbVie Inc., Amgen Inc., Arcutis Biotherapeutics, Inc., Bristol-Myers Squibb Company, Dermavant Sciences, Inc., Eli Lilly and Company, LEO Pharma A/S, Novartis Pharmaceuticals Corporation, Ortho Dermatologics, Pfizer Inc., Sun Pharmaceutical Industries Ltd.; Speakers Bureau: Amgen Inc., Arcutis Biotherapeutics, Inc., Bristol-Myers Squibb Company, Dermavant Sciences, Inc., LEO Pharma A/S, Pfizer Inc.

The Global and Integritas planners and managers do not have anything to disclose. 

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Begin Activity
available resources
linked resources
Suggested Reading

Answers to Everyday Practice Challenges in Dermatology

Focus on Psoriasis